Compile Data Set for Download or QSAR
maximum 50k data
Found 1807 of ic50 data for polymerid = 997
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM120943(US8716296, 89)
Affinity DataIC50:  0.00500nMpH: 7.5Assay Description:All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50 μl reaction volume. The reaction mixt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM120941(US8716296, 82)
Affinity DataIC50:  0.0150nMpH: 7.5Assay Description:All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50 μl reaction volume. The reaction mixt...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM120934(US8716296, 2)
Affinity DataIC50:  0.0180nMpH: 7.5Assay Description:All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50 μl reaction volume. The reaction mixt...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM120936(US8716296, 5 | US8716296, 6)
Affinity DataIC50:  0.0190nMpH: 7.5Assay Description:All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50 μl reaction volume. The reaction mixt...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM120942(US8716296, 83)
Affinity DataIC50:  0.0290nMpH: 7.5Assay Description:All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50 μl reaction volume. The reaction mixt...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM120935(US8716296, 3)
Affinity DataIC50:  0.0390nMpH: 7.5Assay Description:All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50 μl reaction volume. The reaction mixt...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM120939(US8716296, 52)
Affinity DataIC50:  0.116nMpH: 7.5Assay Description:All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50 μl reaction volume. The reaction mixt...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM120936(US8716296, 5 | US8716296, 6)
Affinity DataIC50:  0.173nMpH: 7.5Assay Description:All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50 μl reaction volume. The reaction mixt...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM126500(US11591322, Compound NVP-2 | US8778951, 310)
Affinity DataIC50: <0.5nMAssay Description:Inhibition of CDK9 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails PubMed
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM444516(US10662186, Compound 38 | US10988476, Compound I-3...)
Affinity DataIC50:  0.920nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM444516(US10662186, Compound 38 | US10988476, Compound I-3...)
Affinity DataIC50:  0.920nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM50139171(Dinaciclib | MK-7965 | SCH-727965 | US11643396, Ex...)
Affinity DataIC50:  1nMAssay Description:Inhibition of CDK9 (unknown origin) expressed in Sf9 insect cells using biotinylated peptide derived Histone H1 as substrate incubated for 1 hr in pr...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM50193093(RGB-286638)
Affinity DataIC50:  1nMAssay Description:Inhibition of CDK9 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails PubMed
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM180827(US9133171, 32)
Affinity DataIC50:  1nMpH: 8.0 T: 2°CAssay Description:Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM120940(US8716296, 53)
Affinity DataIC50:  1.08nMpH: 7.5Assay Description:All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50 μl reaction volume. The reaction mixt...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM167699(US9073922, 186 | US9796708, Example 186)
Affinity DataIC50:  1.20nMAssay Description:Inhibition of CDK9 (unknown origin) using Ulight-labeled substrate by TR-FRET LANCE methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM120938(US8716296, 51)
Affinity DataIC50:  1.25nMpH: 7.5Assay Description:All kinase assays were performed in 96-well FlashPlates from Perkin Elmer/NEN (Boston, Mass., USA) in a 50 μl reaction volume. The reaction mixt...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM25036(CHEMBL393525 | N'-[(1E)-{6-bromoimidazo[1,2-a]pyri...)
Affinity DataIC50:  1.40nMAssay Description:Inhibition of CDK9 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM50263013(CHEMBL4079206)
Affinity DataIC50:  1.90nMAssay Description:Inhibition of human CDK9More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM50363196(CHEMBL1944698)
Affinity DataIC50:  2nMAssay Description:Inhibition of human CDK9More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM180853(US9133171, 58)
Affinity DataIC50:  2nMpH: 8.0 T: 2°CAssay Description:Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM167859(US9073922, 356)
Affinity DataIC50:  2nMAssay Description:CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM167858(US9073922, 355)
Affinity DataIC50:  2nMAssay Description:CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM180843(US9133171, 48)
Affinity DataIC50:  2nMpH: 8.0 T: 2°CAssay Description:Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased fro...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM50600028(CHEMBL5190816)
Affinity DataIC50:  2nMAssay Description:Inhibition of CDK9 (unknown origin)More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
In DepthDetails PubMed
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM180799(US9133171, 13 | US9133171, 14 | US9133171, 4)
Affinity DataIC50:  2nMpH: 8.0 T: 2°CAssay Description:Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM180823(US9133171, 28)
Affinity DataIC50:  2nMpH: 8.0 T: 2°CAssay Description:Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM180824(US9133171, 29 | US9133171, 30 | US9133171, 31)
Affinity DataIC50:  2nMpH: 8.0 T: 2°CAssay Description:Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM180824(US9133171, 29 | US9133171, 30 | US9133171, 31)
Affinity DataIC50:  2nMpH: 8.0 T: 2°CAssay Description:Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM180851(US9133171, 56)
Affinity DataIC50:  2nMpH: 8.0 T: 2°CAssay Description:Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchase from...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM167860(US9073922, 357)
Affinity DataIC50:  2nMAssay Description:CDK9 enzyme activities were measured using LANCE ULight TR-FRET kinase assay reagents (PerkinElmer, Waltham, Mass.). Compounds were directly added in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM180815(US9133171, 20)
Affinity DataIC50:  2nMpH: 8.0 T: 2°CAssay Description:Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased fro...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM180819(US9133171, 24)
Affinity DataIC50:  2nMpH: 8.0 T: 2°CAssay Description:Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased fro...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM180824(US9133171, 29 | US9133171, 30 | US9133171, 31)
Affinity DataIC50:  2nMpH: 8.0 T: 2°CAssay Description:Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased fro...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM180836(US9133171, 41)
Affinity DataIC50:  2nMpH: 8.0 T: 2°CAssay Description:Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased fro...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM180837(US9133171, 42)
Affinity DataIC50:  2nMpH: 8.0 T: 2°CAssay Description:Recombinant full-length His-tagged human CDK9 and CycT1, expressed in insect cells and purified by Ni-NTA affinity chromatography, were purchased fro...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM444542(US10662186, Compound 62 | US10988476, Compound I-6...)
Affinity DataIC50:  2.44nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM444542(US10662186, Compound 62 | US10988476, Compound I-6...)
Affinity DataIC50:  2.44nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM50186373(CHEMBL424696 | N-(5-(2-(cyclohexyloxy)pyrimidin-4-...)
Affinity DataIC50:  2.5nMAssay Description:Inhibition of CDK9More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM354126(US9796708, Example 1358 | trans-4-{4-[5-fluoro-4-(...)
Affinity DataIC50:  2.60nMAssay Description:Inhibition of CDK9 (unknown origin) using Ulight-labeled substrate by TR-FRET LANCE methodMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM454552(US10717746, Example 33 | US10717746, Example 35)
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM454555(US10717746, Example 36)
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM454556(US10717746, Example 37)
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM454557(US10717746, Example 38)
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM454558(US10717746, Example 39)
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM454559(US10717746, Example 40 | US10717746, Example 41)
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM454559(US10717746, Example 40 | US10717746, Example 41)
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM454561(US10717746, Example 42)
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM454563(US10717746, Example 44)
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 9(Homo sapiens (Human))
Ingenium Pharmaceuticals

US Patent
LigandPNGBDBM454564(US10717746, Example 45)
Affinity DataIC50: <3nMAssay Description:Activity of CDK9 was determined in-vitro using a mobility shift assay on a Caliper LC3000 reader (Caliper/PerkinElmer), which measures fluorescence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 1807 total ) | Next | Last >>
Jump to: